These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38430375)

  • 41. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
    J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.
    Moutafi M; Koliou GA; Papaxoinis G; Economopoulou P; Kotsantis I; Gkotzamanidou M; Anastasiou M; Pectasides D; Kyrodimos E; Delides A; Giotakis E; Papadimitriou NG; Panayiotides IG; Perisanidis C; Fernandez AI; Xirou V; Poulios C; Gagari E; Yaghoobi V; Gavrielatou N; Shafi S; Aung TN; Kougioumtzopoulou A; Kouloulias V; Palialexis K; Gkolfinopoulos S; Strati A; Lianidou E; Fountzilas G; Rimm DL; Foukas PG; Psyrri A
    Cancer Res Commun; 2023 Aug; 3(8):1514-1523. PubMed ID: 37575280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Park S; Oh D; Choi YL; Chi SA; Kim K; Ahn MJ; Sun JM
    Cancer; 2022 Jun; 128(11):2148-2158. PubMed ID: 35319779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis.
    Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL
    Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
    Zhu P; Wang Y; Zhang W; Liu X
    Medicine (Baltimore); 2021 Jan; 100(4):e24339. PubMed ID: 33530227
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
    Paz-Ares L; Spira A; Raben D; Planchard D; Cho BC; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Hui R; Murakami S; Spigel D; Senan S; Langer CJ; Perez BA; Boothman AM; Broadhurst H; Wadsworth C; Dennis PA; Antonia SJ; Faivre-Finn C
    Ann Oncol; 2020 Jun; 31(6):798-806. PubMed ID: 32209338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
    Paz-Ares L; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Musso E; Havel L; Bondarenko I; Losonczy G; Conev N; Mann H; Dalvi TB; Jiang H; Goldman JW
    ESMO Open; 2022 Apr; 7(2):100408. PubMed ID: 35279527
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
    Leighl NB; Redman MW; Rizvi N; Hirsch FR; Mack PC; Schwartz LH; Wade JL; Irvin WJ; Reddy SC; Crawford J; Bradley JD; Stinchcombe TE; Ramalingam SS; Miao J; Minichiello K; Herbst RS; Papadimitrakopoulou VA; Kelly K; Gandara DR
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
    Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
    Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8.
    Hecht M; Gostian AO; Eckstein M; Rutzner S; von der Grün J; Illmer T; Hautmann MG; Klautke G; Laban S; Brunner T; Hinke A; Becker I; Frey B; Semrau S; Geppert CI; Hartmann A; Balermpas P; Budach W; Gaipl US; Iro H; Fietkau R
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33023982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
    Garon EB; Spira AI; Goldberg SB; Chaft JE; Papadimitrakopoulou V; Cascone T; Antonia SJ; Brahmer JR; Camidge DR; Powderly JD; Wozniak AJ; Felip E; Wu S; Ascierto ML; Elgeioushi N; Awad MM
    J Thorac Oncol; 2023 Aug; 18(8):1094-1102. PubMed ID: 37146752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
    Cirillo A; Marinelli D; Romeo U; Messineo D; De Felice F; De Vincentiis M; Valentini V; Mezi S; Valentini F; Vivona L; Chiavassa A; Cerbelli B; Santini D; Bossi P; Polimeni A; Marchetti P; Botticelli A
    BMC Cancer; 2024 Apr; 24(1):430. PubMed ID: 38589857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Kim DH; Lim ST; Kim HR; Kang EJ; Ahn HK; Lee YG; Sun S; Kwon JH; Lee SC; Lee HW; Kim MK; Keam B; Park KU; Shin SH; Yun HJ
    Oral Oncol; 2024 Apr; 151():106739. PubMed ID: 38458039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab.
    Lambert SL; Zhang C; Guo C; Turan T; Masica DL; Englert S; Fang Y; Sheridan J; McLaughlin RT; Tribouley C; Vosganian G; Afar D
    J Immunother; 2022 Apr; 45(3):167-179. PubMed ID: 35034046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
    BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.